A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.

ABSTRACT:

Purpose

This research examined the cost-effectiveness of adding empagliflozin to standard of care (SoC) compared with SoC alone for treatment of heart failure with reduced ejection fraction (HFrEF) from the perspective of healthcare payers in the United Kingdom (UK), Spain and France.

Methods

A lifetime Markov cohort model was developed to simulate patients' progression through health states based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The model predicted risk of death, hospitalisation for worsening heart failure (HHF), treatment-related adverse events, and treatment discontinuation each monthly cycle. Clinical inputs and utilities were derived from EMPEROR-Reduced trial data, supplemented by published literature and national costing databases. C

SUBMITTER: Tafazzoli A 

PROVIDER: S-EPMC10550866 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature